Company: MLTX
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001821586-25-000011
Chunk: 112

Company: MoonLake Immunotherapeutics
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 112
---
 

The Company operates a defined benefit pension plan in Switzerland (the "Plan”) and a defined contribution pension plan in the United Kingdom, in accordance with local regulations and practices. As of March 31, 2025, the Plan covers the Company’s employees in Switzerland with benefits in the event of death, disability, retirement, or termination of employment. Components of Net Periodic Benefit Cost under the Plan(in thousands)Three Months Ended March 31, 2025Three Months Ended March 31, 2024Service Cost$76$71Interest Cost88Expected return on plan assets(19)(15)Amortization of unrecognized loss33Prior service (credit) recognized in current year(2)(3)Net periodic benefit cost$66$64The components of net periodic benefit cost other than the service cost component are included in general and administrative expense in the Company's condensed consolidated statements of operations and comprehensive loss.Employer Contributions under the PlanFor the three months ended March 31, 2025, contributions of $70 thousand (CHF 63 thousand) were made to the Plan. The Company presently anticipates contributing an additional estimated amount of $210 thousand (CHF 189 thousand) to fund the Plan in 2025 for a total of $280 thousand (CHF 252 thousand).

Note 12 — Shareholders’ Equity

Class A Ordinary Shares(1)Class C Ordinary Shares(1)Total Number of Ordinary SharesAuthorizedIssued and OutstandingAuthorizedIssued and OutstandingAuthorizedIssued and OutstandingBalance at January 1, 2025500,000,00063,077,431100,000,000841,269600,000,00063,918,700Conversion of Class C Ordinary Shares into Class A Ordinary Shares—111,949—(111,949)——Option exercised and converted under the Employee Stock Option Plan—93,347———93,347Issuance of Restricted Stock Awards under the Equity Incentive Plan—191,526———191,526Balance at March 31, 2025500,000,00063,474,253100,000,000729,320600,000,00064,203,573(1) Fully paid-in registered shares with a par value of $0.0001 

19

MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2025(Unaudited)

Class A Ordinary SharesOn April 6